/
CHRS
$1.45-$0.05 (-3.33%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$231.4M
154M shares
52-week range
$0.72 – $2.62
39% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.60%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-12.38
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $356.1M | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | $42.2M |
| Cost of revenue | $3.2M | $17.1M | $37.7M | $57.6M | $70.1M | $159.0M | $117.6M | $17.7M |
| Gross profit | −$1.7M | $339.0M | $438.2M | $269.0M | $141.0M | $98.3M | $149.4M | $24.4M |
| Gross margin | -107.9% | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| R&D | $110.2M | $94.2M | $142.8M | $363.1M | $199.4M | $109.4M | $93.3M | $105.0M |
| Operating income | −$204.4M | $107.8M | $156.3M | −$263.9M | −$256.9M | −$203.2M | −$111.7M | −$179.5M |
| EBITDA | −$204.4M | $111.0M | $161.8M | −$260.7M | −$255.6M | −$193.9M | $60.9M | −$170.2M |
| Net income | −$209.3M | $89.8M | $132.2M | −$287.1M | −$291.8M | −$237.9M | $28.5M | −$170.3M |
| Net margin | -13453.7% | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (diluted) | -3.22 | 1.23 | 1.62 | -3.81 | -3.76 | -2.53 | 0.25 | -1.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $62M | $-1.01 | $-1.60–$-0.71 | 2 |
| 2027 | $88M | $-0.64 | $-1.01–$-0.45 | 2 |
| 2028 | $184M | $-0.48 | $-0.74–$-0.28 | 4 |
| 2029 | $264M | $-0.14 | $-0.22–$-0.10 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Coherus Oncology, Inc. Common Stock
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
www.coherus.com- Employees
- 145
- IPO / List date
- Nov 6, 2014
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds CHRS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 331,700 | $560.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CHRS yet.
